Thursday, April 04, 2024
PixCell Medical, a leading provider of innovative point-of-care diagnostic solutions, has announced a strategic distribution partnership with Medline, further expanding its reach following recent agreements with Henry Schein and Thermo Fisher Scientific. This partnership signifies a significant milestone in PixCell Medical's growth strategy, aimed at making its flagship product, the HemoScreen point-of-care Complete Blood Count (CBC) analyzer, more accessible across the United States.
Medline Industries, a prominent medical supply distributor, will play a crucial role in ensuring seamless access to PixCell Medical's advanced diagnostic technology for healthcare facilities of all sizes. The collaboration with Henry Schein, a global leader in healthcare solutions, will leverage its extensive distribution network to make the HemoScreen analyzer readily available to healthcare professionals nationwide. Additionally, Thermo Fisher Scientific, known for its scientific expertise, will contribute to broadening the reach of the HemoScreen analyzer within the scientific research and laboratory community.
These strategic partnerships align with PixCell Medical's commitment to advancing patient care by delivering accurate and timely diagnostic solutions directly to the point of need. The HemoScreen analyzer provides rapid and precise CBC results within minutes, empowering healthcare professionals with actionable insights for timely diagnosis and treatment decisions. Its compact design and user-friendly interface enhance efficiency and workflow optimization in various healthcare settings, including clinics, emergency departments, and laboratories.
PixCell Medical's recent distribution agreements underscore its dedication to fostering strategic partnerships that drive market penetration and enhance customer reach. Through these collaborations, PixCell Medical aims to advance healthcare delivery by making cutting-edge diagnostic technology accessible and affordable across diverse healthcare settings.
Source: prnewswire.com
